pain therapeutics
Pain Therapeutics refocuses on Alzheimer’s after FDA turns down abuse-deterrent opioid painkiller
August 7, 2018Manufacturing and Production, Research and Development, Sales and Marketing FDA, Remoxy, opioid crisis, opioids, pain therapeutics, pharma
The FDA has voted to reject Texas-based Pain Therapeutics’ abuse deterrent opioid painkiller Remoxy (oxycodone), leading the company to consider …
FDA panels vote to reject Pain Therapeutics’ abuse-deterrent opioid drug
June 27, 2018Research and Development, Sales and Marketing Remoxy, opioid crisis, opioids, pain therapeutics, pharma
Drug development firm Pain Therapeutics has revealed that its abuse-deterrent opioid medication Remoxy has been rejected by an FDA advisory …
Blocking pain – a long-term mission for pharma research
October 5, 2011Research and Development chronic pain, neuropathic pain, pain therapeutics
Pain is a common, yet complex, clinical problem and one which remains an area of unmet need. There are however, …
Nycomed gains new European licence for cancer pain spray
July 4, 2011Sales and Marketing Nycomed, cancer pain, pain therapeutics
The European Commission has approved Nycomed’s Instanyl in a single-dose nasal spray for the treatment of breakthrough pain in cancer …
Grunenthal in talks to sell pain drug portfolio
May 19, 2011Sales and Marketing Grunenthal, Stada, chronic pain, pain therapeutics
Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain …
Pfizer acquires King Pharmaceuticals for $3.6bn
October 13, 2010Sales and Marketing King Pharmaceuticals, Pfizer, pain therapeutics
Pfizer is to purchase King Pharmaceuticals for $3.6 billion to significantly strengthen its pain portfolio and continue to diversify its …
Pfizer forced to halt pain drug trials
July 20, 2010Research and Development Pfizer, chronic pain, pain therapeutics, tanezumab
Pfizer has been told by the FDA to suspend trials of its novel injectable biotherapeutic tanezumab for chronic low back …
Sanofi signs Indian pain drug development deal
May 5, 2010Research and Development Glenmark, Sanofi-Aventis, chronic pain, pain therapeutics
Sanofi-Aventis has signed an agreement with Indian firm Glenmark Pharmaceuticals to develop novel agents for the treatment of chronic pain. …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
